About Brian Henick
- Accolades
-
-
Immunotherapy
-
Peritoneal Mesothelioma
-
Pleural and Lung Cancer
-
Board Certified in Thoracic Surgery
-
Get to Know Dr. Brian Henick
Medical oncologist Dr. Brian Henick specializes in thoracic malignancies, including lung cancer and mesothelioma, and in personalizing patient care through novel therapeutics.
Henick believes in a multidisciplinary approach to treatment that includes the computational study of cancer immunobiology, the latest advancement in cancer care.
With every patient he serves, his goal is improving the current treatment strategy by maximizing the vast resources of one of the country’s leading cancer centers and its mesothelioma doctors.
Learn More About Mesothelioma Treatment
The National Cancer Institute has recognized the Columbia University Herbert Irving Comprehensive Cancer Center as an elite Comprehensive Cancer Center for more than 30 years.
Henick takes pride in staying attuned to the values and needs of each individual. His areas of treatment expertise include esophageal cancer and thymoma through the field of hematology.
He also serves as an associate professor of medicine at the Columbia University Irving Medical Center.
Specialties of Dr. Brian Henick
- Immunotherapy
- Lung cancer
- Pleural mesothelioma
- Esophageal cancer
- Hematology
- Oncology
- Thoracic cancers
Dr. Brian Henick’s Experience and Medical Education
- Columbia University Herbert Irving Comprehensive Cancer Center
- Yale New Haven Hospital (Fellowship, residency, internship)
- Rutgers New Jersey Medical School
Awards and Other Recognitions
- ASCO Journals Editorial Fellowship
- Conquer Cancer/ASCO Foundation Merit Award
- Conquer Cancer/ASCO Young Investigator Award
- Society for Immunotherapy of Cancer Sparkathon
- Gold Humanism Honor Society
Publications of Dr. Brian Henick
- Henick, B. (2020, February 11). Elite Intratumoral T-cell Clonotypes (The 1%) Effect “Trickle-Down Cytotoxicity.” Clinical Cancer Research.
- Zugazagoitia, J. et al. (2019, October 9). Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology.
- Henick, B. et al. (2014, December 18). The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Thoracic Targets.
Disclaimer: Dr. Brian Henick has no professional affiliation with Asbestos.com.

Get a Free Treatment Guide Sent Overnight
Get Yours NowFind Ways to Pay for Treatment Costs
Get StartedFind an Active Mesothelioma Clinical Trial
Find NowGet a Free Treatment Guide Sent Overnight
Find Ways to Pay for Treatment Costs
Find an Active Mesothelioma Clinical Trial
1 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- Columbia University Irving Medical Center. (n.d.). Brian Henick, MD. Retrieved from: https://www.columbiadoctors.org/brian-henick-md#research
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Thank you for your feedback. Would you like to speak with a Patient Advocate?
Related Topics
Share this article
Last Modified August 7, 2020